As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >


Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >


Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >


27, Rue Léonard-de-Vinci –
Parc Technologique Léonard-de-Vinci – CP8010 Lisses
91008 EVRY Cedex – FRANCE
Phone: +33 1 69 89 80 80

Jean-Marc CHERMETTE: President & CEO
Site Web >
Sebia - Genopole's Company Sebia - Genopole's Company

#Health / Well-being #Scientific Instrumentation

  • In vitro diagnostics
  • Clinical biochemistry
  • Electrophoresis
  • Instruments
  • Reagents
  • Monoclonal gammopathies, Hemoglobinopathies, Diabetes
  • Chronic alcohol abuse

Field of Activity

Design, manufacture and commercialization of in vitro diagnostic systems (instruments and reagents) for medical biology laboratories.

Since its incorporation 50 years ago, SEBIA has become a global leader in innovative electrophoretic in vitro diagnostic systems and particularly in the field of capillary electrophoresis.
Electrophoresis consists in the use of an electrical field to separate the proteins contained in biological samples. The most recent capillary electrophoresis technique is applied in the dedicated automated systems: the CAPILLARYS range (CAPILLARYS 2 Flex Piercing, CAPILLARYS 2 Neonat Fast and Capillarys 3) and MINICAP Flex Piercing.

The HYDRASYS range (ASSIST, HYDRASYS 2 SCAN, HYDRASYS 2 SCAN FOCUSING) utilizes an agarose gel as a support.

The electrophoresis technique is a leading technology in the diagnosis of immune system diseases such as myeloma, hemoglobin abnormalities, HbA1c and the detection of other protein markers.
SEBIA’s R&D efforts are delivering results in two fields:

  • The development of fully automated high-throughput systems with networking capabilities with the powerful PHORESIS CORE software, plus a full range of diagnostic tests: proteins, lipoproteins, hemoglobin, HbA1c. SEBIA recently introduced the Capillarys 3 program, including several types of complementary instruments (Capillarys 3 TERA and TERA M.C) offering to all kind of laboratories the modularity and flexibility required in today’s global organization of lab work.
  • SEBIA products are available in 120 countries, through a network of 14 subsidiaries and representative offices and a broad network of distributors.

Moreover SEBIA offers high quality products and services throughout the world.
Sebia maintains close links with the medical community, including university labs associated with its research work and disease specialists developing applications. Sebia has also started collaborations with several associations involved in research projects that bring information and support to patients suffering from myeloma and to their families.

  • Further Information

    Annual turnover: €250M
    > 700 staff members worldwide
    World leader in the IVD field using the electrophoresis technology. Strong innovation capacity. Number 1 company for the diagnosis of monoclonal gammopathies. Major player in the fields of hemoglobin disorders and diabetes through the HbA1c test. High-level scientific and technical support. Education.
    Innovation assets:
    50 years of experience in electrophoresis technology. A renowned company worldwide for the diagnosis of multiple myeloma. Fully integrated company, with all the departments concentrated in Lisses (R&D, manufacturing, regulatory affairs, quality assurance, marketing, commercial, after sales service, scientific assistance and logistics).
    Other facts:
    Export represents more than 85% of Sebia’s sales turnover.

Genopole’s Companies

#Health / Well-being

In same field

BioHive - Genopole Company Shaker - Gene.iO


BioHive provides advanced analysis for dermatological products using innovative skin organoids derived from human stem cells, for toxicity and efficacy evaluations.

Alt Biotech - Genopole's Company Gene.iO#3

Alt Biotech

Alt Biotech offers an innovative bioproduction platform for non-therapeutic recombinant proteins: productive, scalable, with low environmental impact

Vitropep -entreprise genopole


Vitropep developed a unique technology allowing to inject certain peptides without cold chain and with self-administration.

Exosome Analytics - Entreprise génopolitaine

Exosome Analytics

Exosome Analytics develops techniques for EVs isolation and highly sensitive detection of protein markers on EVs for their application in liquid biopsy.



Platform for the bioproduction of RNA through fermentation in eukaryotic cells, a paradigm shift from in vitro synthesis

Kyron.Bio - Genopole's Company


Kyron.Bio is a biotech company using synthetic biology to produce new therapies with high yield, activity, and stability standards.

CGenetix - Entreprise génopolitaine


CGenetix, is a medTech start-up developing in vitro medical diagnostic devices for the follow-up of transplant patients.

EndoGene.Bio - Genopole's Company


Research & development for an in vitro diagnostic tool for endometriosis

Exosome Analytics - Entreprise génopolitaine

Exosome Analytics

Exosome Analytics develops techniques for EVs isolation and highly sensitive detection of protein markers on EVs for their application in liquid biopsy.

Maison M - Startup génopolitaine

Maison M

Personalized and sustainable Cosmetic House inspired by various and unique beauties. The innovative Maison M lipstick delivers any shade customized by its user.

Cell Environment - Genopole's company

Cell Environment

Cell Environment is a company focusing on DNA damage detection involving unique and repeated sequences such as telomere and centromere sequences.

Innovhem - Entreprise génopolitaine


Our mission is to improve the management of Red Blood Cell diseases and in particular Sickle Cell Disease

StemSelect - Entreprise génopolitaine


The aim of StemSelect is to pave the way for a general access to cell therapy. The company develops a rapid isolation method of stem cells derived from one’s own fat tissue.

Synsight - Genopole's Company


Synsight is a company specializing in the discovery and preclinical development of new therapeutic molecules, based on a proprietary, integrated platform, combining artificial intelligence, molecular modeling and a functional experimental screening approach of High-Content Screening (HCS ).

IntegraGen - Genopole's Company


IntegraGen’s mission is to translate molecular research to clinical practice through the identification of novel genetic biomarkers and the subsequent commercialization of molecular diagnostic tests based on these discoveries.

Généthon - Genopole's Laboratory


Discovery, development and production of innovative therapies for rare genetic diseases, notably neuromuscular diseases.



Enterome develops and commercializes therapies for disorders associated with disruption of the intestinal microbiota.

Enalees - Genopole Company 2024


Enalees conceives, develops and markets next-generation rapid molecular diagnosis tests for veterinarians, and furthermore screening tests for SARS-CoV-2.

logo abcell Bio - Genopole's Companie


Abcell-bio is a laboratory specializing in the isolation of human hematopoietic stem cells and primary cells derived from perinatal tissue and cord blood.

Logo Ab Science - Genopole's company

AB Science

Research, development and commercialization of tyrosine kinase inhibitors as targeted therapy for pathologies with unmet medical needs.

View all >
With the support from
Région île de France